Literature DB >> 7776839

Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2.

A G Hohmann1, W J Martin, K Tsou, J M Walker.   

Abstract

The effects of a potent synthetic cannabinoid WIN 55,212-2 on nociceptive responses of wide dynamic range (WDR) neurons in the lumbar spinal cord were investigated in anesthetized rats. WDR neurons were identified by their responses to innocuous brushing and to a range of pressure stimuli from innocuous to noxious. Noxious pressure was applied to regions of the ipsilateral hind paw corresponding to the receptive field of the neuron. WIN 55,212-2 (125 micrograms/kg and 250 micrograms/kg, i.v.) produced a profound inhibition of firing evoked by the noxious pressure stimulus. By contrast, the cannabinoid did not alter the evoked activity of non-nociceptive neurons in response to non-noxious levels of stimulation. Treatment with either vehicle or the inactive enantiomer WIN 55,212-3 (250 micrograms/kg) failed to alter noxious stimulus-evoked activity of WDR neurons. These data provide direct evidence for cannabinoid-mediated inhibition of pain neurotransmission in the spinal dorsal horn. The site of action for these effects remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776839     DOI: 10.1016/0024-3205(95)00196-d

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  21 in total

Review 1.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

2.  Bilateral changes of cannabinoid receptor type 2 protein and mRNA in the dorsal root ganglia of a rat neuropathic pain model.

Authors:  Ivana Hradilová Svízenská; Václav Brázda; Ilona Klusáková; Petr Dubový
Journal:  J Histochem Cytochem       Date:  2013-05-08       Impact factor: 2.479

3.  Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation.

Authors:  M Tognetto; S Amadesi; S Harrison; C Creminon; M Trevisani; M Carreras; M Matera; P Geppetti; A Bianchi
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia.

Authors:  J D Richardson; L Aanonsen; K M Hargreaves
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

6.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

7.  The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.

Authors:  T J Price; G Helesic; D Parghi; K M Hargreaves; C M Flores
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

8.  Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices.

Authors:  Ying-Ching Liang; Chiung-Chun Huang; Kuei-Sen Hsu; Tomoyuki Takahashi
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

9.  CB1 cannabinoid receptor activation inhibits a neural correlate of song recognition in an auditory/perceptual region of the zebra finch telencephalon.

Authors:  Osceola Whitney; Ken Soderstrom; Frank Johnson
Journal:  J Neurobiol       Date:  2003-09-05

Review 10.  Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS.

Authors:  N Murataeva; A Straiker; K Mackie
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.